Recent news on Infliximab

Infliximab Effective for Ulcerative Colitis for Up to 2 years ...  -  25 May 2007
DG NewsWASHINGTON, DC -- May 24, 2007 -- Extensions trials of infliximab therapy for ulcerative colitis show that infliximab responders with initial moderate to

New Analysis Of Data Shows Treatment With Abbott's HUMIRA ...  -  25 May 2007
Medical News Today (press release),...in these patients if they have also lost response to or are intolerant to infliximab, the only other approved biologic for treatment of Crohn's disease.

Long-term ulcerative colitis study shows Remicade responders ...  -  25 May 2007
News-Medical.net,...who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

Infliximab May Not Benefit Patients With COPD  -  May 1, 2007
Medscape (subscription)May 1, 2007 — Infliximab was not beneficial in patients with moderate to severe chronic obstructive pulmonary disease after 6 months of treatment,

Infliximab Shows No Benefit in COPD  -  May 2, 2007
MedPage Today,Explain to interested patients that infliximab is indicated for the treatment of rheumatoid arthritis, which has led investigators to study its use in other

Infliximab fails to improve chronic obstructive pulmonary disease ...  -  May 2, 2007
News-Medical.net,The results of the randomized, double-blind, placebo-controlled trial of infliximab were published in the first issue of the May American Journal of

Infliximab Fails Test in Two Rheumatologic Diseases  -  Apr 30, 2007
MedPage Today,Explain that these studies tested infliximab (Remicade) a monoclonal antibody against tumor necrosis factor-alpha, and found it had no benefit and might

Infliximab for Maintenance of Glucocorticosteroid-Induced ...  -  Apr 30, 2007
Annals of Internal MedicineIntervention: Participants were randomly assigned in a 2:1 ratio to receive infliximab (5 mg/kg of body weight) or placebo. Sixteen patients were assigned

Adding Infliximab to the Treatment Regimen for Polymyalgia Rheumatica  -  Apr 30, 2007
Annals of Internal MedicineThe summary below is from the full report titled "Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica.

Adding Infliximab to the Treatment Regimen for Giant Cell Arteritis  -  Apr 30, 2007
Annals of Internal MedicineThe summary below is from the full report titled "Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis.

Infliximab plus Prednisone or Placebo plus Prednisone for the ...  -  Apr 30, 2007
Annals of Internal MedicineAlthough infliximab has been used occasionally in steroid-resistant cases, its efficacy has not been demonstrated in a controlled study.

UCB says long-term data shows Cimzia drug is 'well tolerated'  -  May 21, 2007
ABCmoney.co.uk,...including patients who had previously received Centocor Inc's infliximab, those treated with monotherapy, or those treated with immunosuppressants.

Adalimumab May Induce Remission of Crohn's Disease  -  May 4, 2007
Medscape (subscription)May 4, 2007 — Adalimumab was effective in inducing remission of Crohn's disease in patients who could not tolerate infliximab treatment, according to the

Promising Drug Fails To Improve COPD Symptoms  -  May 7, 2007
Medical News Today (press release),The results of the randomized, double-blind, placebo-controlled trial of infliximab were published in the American Journal of Respiratory and Critical Care

New Therapy For Patients With Crohn's Disease Identified By ...  -  May 7, 2007
Medical News Today (press release),A study led by Mayo Clinic found that adalimumab (HUMIRA®)) is an effective treatment for adults with Crohn's disease who do not respond to infliximab

Researchers Identify New Therapy for Patients with Crohn's Disease  -  May 3, 2007
DG NewsOne common therapy is a series of intravenous infusions of infliximab, which blocks tumor necrosis factor, an important cause of inflammation in Crohn's

Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis: Are ...  -  Apr 30, 2007
Annals of Internal MedicineTwo studies in this issue tested the hypothesis that infliximab, a monoclonal antibody against TNF, can reduce corticosteroid exposure in patients with GCA

Anti-Tumor Necrosis Factor Drug Doesn't Help Two Inflammatory Diseases  -  May 4, 2007
Medical News Today (press release),Two studies in the May 1, 2007, Annals of Internal Medicine find that infliximab, a widely used anti-tumor necrosis drug, has no benefit in patients

Rheumatoid arthritis drug link to atherosclerosis  -  May 11, 2007
Healthcare Republic (press release),The study showed RA patients taking the tumour necrosis factor (TNF)-alpha blocker infliximab had an increased atherogenic index and higher level of total

Treatment of Crohn Disease with Anti-Tumor Necrosis Factor Agent  -  Apr 30, 2007
Annals of Internal MedicineThe full report is titled "Adalimumab Induction Therapy for Patients with Crohn Disease Previously Treated with Infliximab: A Randomized Trial.

Drug listing could help Jewish Crohn’s patients  -  May 1, 2007
Australian Jewish News,The Pharmaceutical Benefits Advisory Committee handed down its decision after six previous attempts by the manufacturers of Infliximab, Schering-Plough,

New Analysis of Data Shows Treatment With Abbott's HUMIRA(R ...  -  May 22, 2007
Earthtimes.org...in these patients if they have also lost response to or are intolerant to infliximab, the only other approved biologic for treatment of Crohn's disease.

Mark marvels at new drug  -  Apr 30, 2007
This is Wiltshire.co.uk,Recently, he was introduced to a new treatment called Infliximab, which attacks the HLA-B27 gene, relieving the sufferer from many of the symptoms.

Gift of his dreams  -  Apr 28, 2007
Melbourne Herald Sun,After reading the Melbourne schoolboy faced a race against time to raise $9000 for a life-changing drug, Infliximab, readers donated much of the money

Crohn's sufferers seeking drug subsidy  -  Apr 26, 2007
The Age,The federal government's pharmaceutical advisory body has recommended sufferers of severe Crohn's disease be given access to the expensive drug Infliximab,

UCB Presents Long-Term CIMZIAâ„¢ Data in Crohn's Disease  -  May 23, 2007
PipelineReview.com (press release),The patients represented a broad population living with moderate to severe Crohn's disease, including patients who had previously received infliximab,

'Mini-antibodies' in first-ever clinical trials  -  May 23, 2007
DrugResearcher.com,There are currently three marketed anti-TNF drugs: Centocor Pharmaceuticals' (Johnson & Johnson's) Remicade (infliximab) for Crohn's Disease and rheumatoid

UCB Presents Long-Term CIMZIA(TM) Data in Crohn's Disease  -  May 22, 2007
PR-Inside.com (Pressemitteilung),The patients represented a broad population living with moderate to severe Crohn's disease, including patients who had previously received infliximab,

Abbott's HUMIRA® (adalimumab) Receives Positive Opinion From ...  -  Apr 30, 2007
Medical News Today (press release),GAIN (Gauging Adalimumab effectiveness in Infliximab Non-Responders) evaluated the efficacy of HUMIRA in 325 patients with moderate to severely active

Alternative Financings Provide Biotechs With More Options  -  May 18, 2007
BioWorld Online,Amgen Inc. and Wyeth Pharmaceuticals Inc.) from Massachusetts General Hospital, while Royalty Pharma acquired an interest in Remicade (infliximab,

Abbott's novel psoriasis biologic shows promise  -  May 10, 2007
In-PharmaTechnologist.com,Remicade (infliximab) and Humira (adalimumab) are used in the treatment of psoriasis arthritis, rheumatoid arthritis and Crohn's disease.

Lonza plans to commercially produce emerging class of drugs  -  May 10, 2007
DrugResearcher.com,Genentech/Biogen Idec's lymphoma treatment Rituxan (infliximab) and colorectal cancer drug Erbitux (cetuximab) sold in Europe by Merck KGaA.

Abbott seeks US and EU approvals for Humira as a treatment for ...  -  May 9, 2007
News-Medical.net,...reducing the signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

Peptech Acquiring EvoGenix In Cash, Stock Deal Worth A$156M  -  May 7, 2007
BioWorld Online,Peptech gets royalties for Remicade (infliximab), for rheumatoid arthritis and Crohn's disease. More royalty cash is paid by Abbott Park, Ill.-based Abbott

Study IDs Crohn's disease therapy  -  May 2, 2007
United Press InternationalROCHESTER, Minn., May 2 (UPI) -- Adalimumab -- sold as Humira -- works on Crohn's disease for those adults who fail on infliximab, sold as Remicade,

Crohn's sufferers seeking drug subsidy  -  26 Apr 2007
Sydney Morning Herald,The federal government's pharmaceutical advisory body has recommended sufferers of severe Crohn's disease be given access to the expensive drug Infliximab,

Inflammation, Asthma, and Tumor Necrosis Factor-alpha  -  Apr 24, 2007
Medscape (subscription)The inhibitors include the monoclonal antibodies against TNF-alpha (infliximab and adalimumab) as well as the soluble TNF-alpha receptor fused to human

Bowel disease relief coming  -  Apr 22, 2007
Melbourne Herald Sun,People with Crohn's disease currently pay up to $45000 a year for Infliximab, while arthritis sufferers pay a maximum prescription of $30.70.

Matt's race against time  -  Apr 21, 2007
Melbourne Herald Sun,The teenager has Crohn's disease and could be treated effectively with injections of the anti-inflammatory drug Infliximab.

Calls for govt to subsidise Crohn drug  -  Apr 20, 2007
The Age,The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the expensive drug Infliximab, also known as Remicade, be listed on the Pharmaceutical

Crohn’s drug may go on PBS  -  Apr 20, 2007
Border Mail,The Pharmaceutical Benefits Advisory Committee has recommended the expensive drug Infliximab, or Remicade, be listed on the Pharmaceutical Benefits Scheme

European Union CHMP Recommends Approval of First and Only Biologic ...  -  Apr 2, 2007
Drug Newswire (press release),Available data do not support further infliximab treatment in pediatric patients not responding within the first 10 weeks of treatment.

Schering-Plough Reports Financial Results for First Quarter of 2007  -  Apr 19, 2007
PR Newswire (press release),27) -- Gained European Commission (EC) approval with Centocor, Inc. of a label extension for REMICADE (infliximab) allowing for greater dosing flexibility

French Guidelines for Pretreatment Screening Inadequate to ...  -  Apr 10, 2007
DG NewsThe last specific TNFalpha inhibitor therapy that these cases had received were the chimeric antibody infliximab (19), the humanised antibody adalimumab

REMICADE(R) Receives Approval in European Union for Dosing ...  -  Mar 30, 2007
Drug Newswire (press release),The EC approval for the dose titration label extension is based on data from the Safety Trial for Rheumatoid Arthritis with REMICADE (infliximab) Therapy

SP delivers again, beating forecasts  -  Apr 20, 2007
Pharma Times (subscription),Sales of Remicade (infliximab) increased 34% to $373 million, driven by growth across all indications. Remicade is a treatment for immune-mediated

Top Euro award for British inventor  -  Apr 18, 2007
Channel 4 News,Millions of patients around the world have been successfully treated with the antibody, registered as the drug Infliximab. He was presented with a lifetime

The Moose in the Room  -  Apr 16, 2007
Scientist,Centocor did $3.5 billion in sales last year, mostly on the success of its chief product, Remicade (infliximab), a tumor necrosis factor (TNF) inhibitor

Study Shows Children With ADHD Who Start On Strattera(R) Are More ...  -  Apr 12, 2007
Medical News Today (press release),...the integration of medical and pharmacy data including clinical utilization management program opportunities for infliximab and the fentanyl patch.

A wonder drug beat my teenage arthritis  -  Apr 10, 2007
Daily Mail,There are three different anti-TNF drugs on the market at present: Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab), delivered either by

In Brief  -  Apr 3, 2007
Nature.com (subscription),Remicade (infliximab) from Centocor of Malvern, Pennsylvania, Erbitux (cetuximab) from New York-based ImClone Systems and Synagis (palivizumab) from

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),Remicade (infliximab; Centocor, subsidiary of Johnson & Johnson of New Brunswick, New Jersey) and Humira (adalimumab; Abbott Laboratories, of Abbott Park,

Singapore growing biopharma strength  -  Apr 2, 2007
DrugResearcher.com,The Singaporean sites manufacture Schering's hepatitis C treatment Peg-Intron (peginterferon alpha-2b) and Remicade (infliximab) for Crohn's disease and

New route to real relief  -  Mar 30, 2007
Calcutta Telegraph,Milan Chetri, consultant in internal medicine at Apollo Gleneagles Hospitals, said: “Drugs like infliximab and etanarcept can stop the progression of

From the Department of Emergency Medicine, Virginia Commonwealth ...  -  Mar 30, 2007
AEM (subscription)Study of Patients Receiving Infliximab for Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) study, 5 and the recently completed PolyHeme study.

Infliximab appears safe in patients with lupus  -  Feb 12, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - Although treatment with the antitumor necrosis factor (TNF)-alpha antibody infliximab prompts certain transient reactions in

Infliximab Significantly Improves and Sustains Productivity in ...  -  Feb 6, 2007
DG NewsTo evaluate the impact of infliximab therapy on patient productivity the investigators conducted a retrospective analysis of data from the Evaluation of

New Analyses Support Infliximab Use for Severe Psoriasis, Show ...  -  Feb 5, 2007
DG NewsA separate analysis of data in the European Infliximab for Psoriasis Efficacy and Safety Study (EXPRESS) trial showed that among subjects with psoriasis

New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of ...  -  Feb 7, 2007
Drug Newswire (press release),In a separate analysis from the Evaluation of Infliximab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II), among patients with severe

Thousands pin hopes on intestinal disease drug approval  -  Feb 5, 2007
The Age,For the seventh time in as many years, the maker of Infliximab — which costs between $3000 and $5000 for a dose that lasts two to three months — have

Remicade therapy shown to increase productivity in psoriatic patients  -  Feb 3, 2007
RxPG NEWS,In the Evaluation of Infliximab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II), REMICADE-treated patients demonstrated a statistically

Biologic Drug Remicade Data Offers 'Great Hope' for Severe ...  -  Feb 2, 2007
Biologic Drug Report,Three-quarters of severe psoriasis patients given biologic drug Remicade (Infliximab) showed a 75 percent improvement in 10 weeks, according to an analysis

Schering-Plough's turnaround is moving on apace  -  Jan 30, 2007
Pharma Times (subscription),Sales of the arthritis drug Remicade (infliximab)advanced 34% to $337 million in the quarter, helped by expanded indications, while Nasonex (mometasone

New work programme for NICE announced  -  Feb 7, 2007
netPR.pl (komunikaty prasowe),Infliximab for ulcerative colitis To appraise the clinical and cost effectiveness of infliximab for ulcerative colitis. Lapatinib for advanced or metastatic

New analyses reinforce efficacy of Remicade in treatment of severe ...  -  Feb 3, 2007
HULIQ,A separate analysis from the European Infliximab for Psoriasis [REMICADE] Efficacy and Safety Study (EXPRESS) trial showed that among study patients with

Remicade therapy productive in patients treated for chronic plaque ...  -  Feb 3, 2007
HULIQ,The Evaluation of Infliximab for Psoriasis in a [REMICADE] Efficacy and Safety Study (EXPRESS II) was a Phase 3, multi-center, randomized, double-blind,

Switching TNF-alpha blockers can be effective for rheumatoid ...  -  Feb 14, 2007
Therapeutics Daily (subscription) (press release),The analysis involved 6739 patients who started new anti-TNF treatment: 876 on adalimumab, 2826 on etanercept and 3037 on infliximab. During a mean of 15 .

Specialty Infusion Brings New Challenges, Solutions to Payers  -  Feb 12, 2007
Atlantic Information Services, Inc.,A blurring of specialty pharmacy and home infusion has resulted in the area of specialty infusion, under which drugs such as Remicade (infliximab),

New NICE guidance on its way  -  Feb 12, 2007
Healthcare Equipment and Supplies,Certolizumab pegol for rheumatoid arthritis; Infliximab for ulcerative colitis; Lapatinib for advanced or metastatic breast cancer; and Rimonabant for

New work programme for NICE announced  -  Feb 8, 2007
Media Newswire (press release),To appraise the clinical and cost effectiveness of infliximab for ulcerative colitis. To appraise the clinical and cost effectiveness of lapatinib plus

Naltrexone may help Crohn's sufferers  -  Feb 5, 2007
Science Daily (press release)The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve .

Mitsubishi/Tanabe merger may be first of many in Japan  -  Feb 5, 2007
Pharma Times (subscription),Tanabe's best-selling drug is Remicade (infliximab) for rheumatoid arthritis, licensed from Johnson & Johnson, and sales for the year ending March 2007 are

An integrated analysis of data from three pivotal trials shows ...  -  Feb 3, 2007
MedIndia,Three pivotal, randomized, placebo-controlled trials showed that more than three-quarters of patients with severe psoriasis receiving REMICADE® (infliximab)

Reimbursement Limitations on Biologic Agents Are Constraining ...  -  Jan 30, 2007
Drug Newswire (press release),...finds that significant reimbursement limitations for biologic agents, including Centocor's Remicade (infliximab), are constraining growth in the drug

Reimbursement Curbs Seen Constraint on Use of Biologic Drugs for ...  -  Jan 30, 2007
Biologic Drug Report,While two new biologic drugs are expected to be approved this year to join Remicade (infliximab) as a treatment for Crohn's disease, a leading research firm

Drip Infusion 100 Receives Approval As Additional Indication Of ...  -  Jan 28, 2007
Medical News Today (press release),...for Drip Infusion 100 (generic name: infliximab) for extended indication of treating "Behcet's disease complicated with refractory uveoretinitis which

Arthritis Clinical Trial Results Revealed  -  Jan 2, 2007
Journal of American Medical Association (subscription),Another trial assessed the potential of combination therapy of methotrexate and infliximab or abatacept for patients with rheumatoid arthritis.

Conversation with…Dr. Jeffrey Hyams Top pediatric GI sees research ...  -  Jan 16, 2007
Connecticut Jewish Ledger,I have had the pleasure of being the primary investigator for the two largest pediatric clinical trials of new medications involving Remicade (infliximab)

Current and Emerging Strategies in Biologic Therapy for IBD  -  Dec 4, 2006
Medscape (subscription)The introduction of the first anti-tumor necrosis factor (TNF)-alpha biologic agent, infliximab, as a treatment for Crohn's disease has revolutionized

REMICADE(R) Receives Approval in European Union for Shortened ...  -  Dec 17, 2006
Drug Newswire (press release),The EC approval of the shortened infusion time is based on data from the ASPIRE (Active Controlled Study of Patients Receiving Infliximab for Treatment of

To keep colds at bay, stock up on sneakers  -  Dec 2, 2006
Nashua Telegraph (subscription),...including the so-called biologic medications etanercept (Enbrel) and infliximab (Remicade). Blood and lymphatic cancers were diagnosed in 69 people;

The Impact Of Immunosuppressive Medications On Cardiovascular ...  -  Dec 1, 2006
Medical News Today (press release),...including the interleukin-1 receptor antagonist anakinra as well as the three TNFá blockers, adalimumab, etanercept, and infliximab.

Cytotoxic and Glucocorticoid Agents Increase CV Risk in Rheumatoid ...  -  Nov 29, 2006
Medscape (subscription)...tumor necrosis factor–alpha antagonists (adalimumab, etanercept, or infliximab), anakinra, cytotoxic agents (azathioprine, cyclosporine, leflunomide),

For RA Cardioprotection, Biologics Found Equal to Methotrexate  -  Nov 29, 2006
MedPage Today,Biologic agents Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab) and Kineret (anakinra) as a group carried the same risk as methotrexate

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional